Skip to search formSkip to main contentSkip to account menu

bismuth subcitrate

Known as: bismuth tripotassium dicitrate [Chemical/Ingredient], Bismuth tripotassium dicitrate, BISSUBCIT 
A mineral compound that is used to treat duodenal and gastric ulcers associated with Helicobacter pylori.
National Institutes of Health

Related topics

Related topics

18 relations

Broader (4)

AntacidsAnti-Infective AgentsAnti-Ulcer AgentOrganometallic Compounds
BismuthBlood Coagulation DisordersChickenpoxDrug Allergy

Narrower (3)

Bismuth subcitrate potassiumPyleraVentrisol-polfa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2003
Highly Cited
2003
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second‐line treatment for Helicobacter pylori infection
Aim : To test the efficacy of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy for the second‐line… 
Highly Cited
1999
Highly Cited
1999
Quadruple Therapy Is Effective for Eradicating Helicobacter pylori After Failure of Triple Proton‐Pump Inhibitor–Based Therapy: A Detailed, Prospective Analysis of 21 Consecutive Cases
Background. Data regarding the effectiveness of second‐line treatment of Helicobacter pylori infection are limited, especially if… 
1993
1993
Biotype and molecular fingerprints of metronidazole-resistant strains of Helicobacter pylori from antral gastric mucosa.
Biotypes, ribosomal RNA gene restriction patterns (ribopatterns), whole-cell protein patterns and plasmid profiles of paired… 
Highly Cited
1991
Highly Cited
1991
Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate.
A study was undertaken to determine the role of Helicobacter pylori in non-ulcer dyspepsia (NUD) and to determine the efficacy of… 
Review
1991
Review
1991
Medical treatment of peptic ulcer disease.
Review
1991
Review
1991
Safety and pharmacokinetics: colloidal bismuth subcitrate.
Recent studies on oral administration of colloidal bismuth subcitrate suggest that, on average, the blood clearance of bismuth… 
Highly Cited
1989
Highly Cited
1989
Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol)
Infection by Campylobacter pylori appears to play a major role in the etiology of gastric disease, but the nature of impairment… 
Highly Cited
1987
Highly Cited
1987
Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins.
This study compares the gastroprotective effects of colloidal bismuth subcitrate (De-Nol) with those of sucralfate and a… 
1986
1986
Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol).
Basal and pentagastrin stimulated gastric secretion was measured in seven patients with duodenal, and six with gastric ulcers… 
1982
1982
A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid.
: The mode of action of colloidal bismuth subcitrate (CBS), a colloidal bismuth preparation often used in the treatment of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)